<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Corticosteroids - inhaled | Management | Corticosteroids - inhaled | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management of people receiving inhaled corticosteroids in primary care."/><meta data-react-helmet="true" property="og:description" content="Covers the management of people receiving inhaled corticosteroids in primary care."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/corticosteroids-inhaled/management/corticosteroids-inhaled/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Corticosteroids - inhaled | Management | Corticosteroids - inhaled | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/corticosteroids-inhaled/management/corticosteroids-inhaled/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Corticosteroids - inhaled</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Corticosteroids - inhaled</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/corticosteroids-inhaled/","name":"Corticosteroids - inhaled"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/corticosteroids-inhaled/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Corticosteroids - inhaled"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Corticosteroids - inhaled: </span><span>Scenario: Corticosteroids - inhaled</span></h1><p class="page-header__lead"><span>Last revised in May 2020</span></p></div><p class="visually-hidden">Covers the management of people receiving inhaled corticosteroids in primary care.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Corticosteroids - inhaled chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Corticosteroids - inhaled"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Corticosteroids - inhaled</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#initiation">Initiation</a><ol aria-label="Sections within Initiation" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-9e0">Basis for recommendation</a></li></ol></li><li><a href="index.html#available-delivery-systems">Available delivery systems</a><ol aria-label="Sections within Available delivery systems" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-f21">Basis for recommendation</a></li></ol></li><li><a href="index.html#choosing-a-delivery-system">Choosing a delivery system</a><ol aria-label="Sections within Choosing a delivery system" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-7f4">Basis for recommendation</a></li></ol></li><li><a href="index.html#contraindications-cautions">Contraindications and cautions</a><ol aria-label="Sections within Contraindications and cautions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-562">Basis for recommendation</a></li></ol></li><li><a href="index.html#pregnancy-breastfeeding">Pregnancy and breastfeeding</a><ol aria-label="Sections within Pregnancy and breastfeeding" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ea4">Basis for recommendation</a></li></ol></li><li><a href="index.html#adverse-effects">Adverse effects</a><ol aria-label="Sections within Adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-e74">Basis for recommendation</a></li></ol></li><li><a href="index.html#minimizing-adverse-effects">Minimizing adverse effects</a><ol aria-label="Sections within Minimizing adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-dcc">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-e31">Basis for recommendation</a></li></ol></li><li><a href="index.html#information-advice">Information and advice</a><ol aria-label="Sections within Information and advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-e32">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="corticosteroids-inhaled" class="ChapterBody-module--wrapper--2HCfk "><h2 id="corticosteroids-inhaled" class="visually-hidden">Scenario: Corticosteroids - inhaled</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1898f206-c036-47c3-876a-ac55ad0a0ec3 --><!-- begin field 91f542a7-aab3-4b4e-b92e-acd900ace98f --><p>From birth onwards.</p><!-- end field 91f542a7-aab3-4b4e-b92e-acd900ace98f --><!-- end item 1898f206-c036-47c3-876a-ac55ad0a0ec3 --></div><section aria-labelledby="initiation" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initiation">What should I consider when initiating inhaled corticosteroids?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0e85d727-64d7-4e1b-8b66-5aca04b69054 --><!-- begin field fb3a679b-7220-4780-a51e-025f1679e141 --><ul><li>Select the most appropriate <a class="topic-reference internal-reference" href="index.html#available-delivery-systems">delivery system</a> for the person being treated, their condition, and the drug being prescribed.</li><li>Ensure that the person knows how to use the device (and check this competence at any review, routine or unscheduled). </li><li>Avoid prescribing inhalers generically — this ensures continuity of device type in future and helps prevent adherence issues that may occur if a different device is given. </li><li>The various inhaled corticosteroids are similar in efficacy and adverse effect profile. However:<ul><li>Qvar and Kelhale products have extrafine particles and are twice as potent as other beclometasone inhalers. </li></ul></li><li>Issue a steroid treatment card to people: <ul><li>Using prolonged high doses (more than 1000 micrograms beclometasone or equivalent) of inhaled corticosteroids (including off-label high doses, and maximum inhaled doses in conjunction with oral corticosteroids).</li><li>Taking inhaled corticosteroids plus drugs that inhibit their metabolism (for example cytochrome P450 inhibitors, such as <a class="topic-reference internal-reference" href="index.html#drug-interactions">HIV protease inhibitors</a>).</li></ul></li></ul><!-- end field fb3a679b-7220-4780-a51e-025f1679e141 --><!-- end item 0e85d727-64d7-4e1b-8b66-5aca04b69054 --></div><section aria-labelledby="basis-for-recommendation-9e0" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-9e0">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9e08d11c-838a-4e5a-90ae-f0a08a064bcf --><!-- begin field 8b2d354b-4ef3-4c3f-bc72-1a709426a329 --><p>These recommendations are based on the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>]<em>, </em>the National Institute for Health and Care Excellence (NICE) guideline <em>Asthma: diagnosis, monitoring and chronic asthma management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020c</a>], and the Medicines and Healthcare products Regulatory Agency (MHRA) advice <em>High dose inhaled steroids: new advice on supply of steroid treatment cards </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2006</a>].</p><!-- end field 8b2d354b-4ef3-4c3f-bc72-1a709426a329 --><!-- end item 9e08d11c-838a-4e5a-90ae-f0a08a064bcf --></div></section></section><section aria-labelledby="available-delivery-systems" class="ChapterBody-module--wrapper--2HCfk "><h3 id="available-delivery-systems">What delivery systems are available for inhaled corticosteroids?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 55094574-453e-43ef-9a8a-d70eb9d83b6f --><!-- begin field 4ecfdebb-a889-4995-9cdf-dbe2dd792268 --><ul><li><strong>Pressurized metered-dose inhalers (pMDIs)</strong><ul><li>In a pMDI, the drug is suspended or dissolved in a propellant (hydrofluoroalkane) within a pressurized container. </li><li>The device is activated by the user pressing down on the top of the container, resulting in the release of a fine spray containing propellant and drug.<ul><li>The person needs to coordinate inspiration and actuation. </li></ul></li><li>pMDIs are the standard type of inhaler for delivering inhaled corticosteroids, and are generally less expensive than other delivery systems. However, they require adequate coordination and dexterity.</li><li>If used correctly, they are at least as effective as other delivery systems. </li></ul></li><li><strong>Spacer devices</strong><ul><li>These are plastic devices with a mouthpiece at one end and a hole, for a pMDI to be inserted, at the other end.</li><li>There are a number of different devices available, but they are not interchangeable and must be compatible with the pMDI used. </li><li>Spacers are useful because they: <ul><li>Remove the need for coordination between actuation of the pMDI and inhalation. </li><li>Slow down the particles of the drug and allow more time for evaporation of the propellant so that more of the drug can be inhaled and deposited in the lungs.</li><li>Reduce the amount of drug deposited in the oropharynx (thereby reducing local adverse effects and the amount of systemic absorption). </li></ul></li><li>Spacers are of particular benefit for: <ul><li>Children who need high doses of inhaled corticosteroids.</li><li>People with a poor inhalation technique.</li><li>People who are prone to candidiasis with inhaled corticosteroids.</li></ul></li></ul></li><li><strong>Dry powder inhalers (DPIs)</strong><ul><li>DPIs do not have a propellant — they deliver the micronized drug and a carrier powder that is inhaled using the person's own inspiratory flow (this requires the person to have sufficient inspiratory effort to breathe in the powder). <ul><li>Many DPIs incorporate dose counters to show the number of doses used, or the number of doses remaining.</li></ul></li><li>DPIs do not require the person to breathe in and press the inhaler at the same time, so are suitable when coordination and dexterity is a problem. </li><li>DPIs are generally more expensive than pMDIs (plus spacer), but are no more effective. </li><li>DPIs are usually larger than pMDIs, but can usually still fit in a pocket. </li></ul></li><li><strong>Breath-actuated MDIs (BA-MDIs)</strong><ul><li>These are automatically activated on inhalation (the person needs to have sufficient inspiratory effort to activate the device). </li><li>BA-MDIs are as effective as pMDIs and are useful when coordination and dexterity is a problem as there is no need to breathe in and press the inhaler at the same time. </li></ul></li><li><strong>Nebulizers</strong><ul><li>Solutions are administered over 5–10 minutes from a nebulizer, usually driven by oxygen, which converts the solution into an aerosol that can be inhaled through a mask or mouthpiece. <ul><li>A mouthpiece is preferable to avoid adverse effects caused by exposure of the skin and eyes to the corticosteroid. </li></ul></li><li>Their main advantage is that no coordination is required by the user, and high doses of drug can be delivered directly to the airways. </li><li>Nebulized corticosteroids are reserved for when inhaled treatment is inadequate.</li></ul></li></ul><!-- end field 4ecfdebb-a889-4995-9cdf-dbe2dd792268 --><!-- end item 55094574-453e-43ef-9a8a-d70eb9d83b6f --></div><section aria-labelledby="basis-for-recommendation-f21" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-f21">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f21073c9-abfb-4514-a7b5-f0422f9fea9a --><!-- begin field 063b1d05-f683-43dc-881d-123320b367b9 --><p>This information is based on the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN)<em> British guideline on the management of asthma</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>], a large Health Technology Assessment (HTA)<em> Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Brocklebank, 2001</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>], the NICE technology appraisal <em>Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2002</a>], the Global Initiative for Asthma (GINA) <em>Global strategy for asthma management and prevention</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA, 2020</a>], and the <em>British National Formulary</em> (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>].</p><!-- end field 063b1d05-f683-43dc-881d-123320b367b9 --><!-- end item f21073c9-abfb-4514-a7b5-f0422f9fea9a --></div></section></section><section aria-labelledby="choosing-a-delivery-system" class="ChapterBody-module--wrapper--2HCfk "><h3 id="choosing-a-delivery-system">What should I consider when choosing a delivery system for inhaled corticosteroids?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0bad7023-b1d2-402b-961f-7c8ba794c5f4 --><!-- begin field 4c91a09d-4fbb-49d3-a46f-aefd2f13f42a --><ul><li><strong>When choosing a delivery system for inhaled corticosteroids, consider:</strong><ul><li><strong>The ability </strong>of the person to develop and maintain an effective technique with the specific device — this may depend on factors such as age, physical barriers (for example, arthritis, muscle weakness), other medical conditions (for example, impaired vision), coordination, cognitive impairment, and inspiratory flow (a minimum inspiratory flow rate is required for use of dry powder inhalers [DPIs] or breath-actuated metered-dose inhalers [BA-MDIs]).<ul><li>For children aged under 3 years, the preferred device is a pressurized metered-dose inhaler (pMDI) with spacer and face mask.</li><li>For children aged 3–5 years, the preferred device is pMDI with spacer and a mouthpiece (if they are able to demonstrate good technique). </li></ul></li><li><strong>The suitability </strong>of the device to the person's (and carer’s) lifestyle, including portability and convenience. </li><li><strong>The person's preference </strong>for, and willingness to use, a particular device. </li><li><strong>Other inhalers the person is using </strong>— minimize the number of inhalers and the number of different types of inhaler used by each person as far as possible. </li><li><strong>Cost</strong> — if more than one device is suitable, choose the device with the lowest overall cost (taking into account the daily required dose and product price per dose). </li></ul></li><li><strong>Only prescribe the inhaler after the person (and/or their carer) has received training in its use and has demonstrated a satisfactory technique. </strong><ul><li>Review the person's inhaler technique and give advice about inhaler technique: <ul><li>At every consultation relating to an asthma attack.</li><li>When there is deterioration in control.</li><li>When the device is changed.</li><li>At every annual review.</li><li>If the person asks for it to be checked. </li></ul></li></ul></li></ul><!-- end field 4c91a09d-4fbb-49d3-a46f-aefd2f13f42a --><!-- end item 0bad7023-b1d2-402b-961f-7c8ba794c5f4 --></div><section aria-labelledby="basis-for-recommendation-7f4" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-7f4">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7f46b89a-326c-46cd-a514-cc6a938b0078 --><!-- begin field 2848458d-ab22-4b9b-81b6-24b4639814c4 --><p>This information is based on the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Chronic obstructive pulmonary disease in over 16s: diagnosis and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>], the NICE guideline <em>Asthma: diagnosis, monitoring and chronic asthma management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020c</a>], the NICE technology appraisal <em>Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2002</a>], and the Global Initiative for Asthma (GINA) <em>Global strategy for asthma management and prevention</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA, 2020</a>].</p><!-- end field 2848458d-ab22-4b9b-81b6-24b4639814c4 --><!-- end item 7f46b89a-326c-46cd-a514-cc6a938b0078 --></div></section></section><section aria-labelledby="contraindications-cautions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="contraindications-cautions">What contraindications and cautions are associated with inhaled corticosteroids?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 92ff79c1-b88f-438f-a79f-97cac035a715 --><!-- begin field 6cb6fae6-819e-4f3b-b339-806ab0666ebb --><ul><li><strong>Contraindications</strong><ul><li>There are no contraindications to the use of inhaled corticosteroids.</li></ul></li><li><strong>Cautions</strong><ul><li>Active (untreated) or quiescent tuberculosis.</li><li>Untreated fungal, bacterial, parasitic, or systemic viral infections, or ocular herpes simplex.</li></ul></li></ul><!-- end field 6cb6fae6-819e-4f3b-b339-806ab0666ebb --><!-- end item 92ff79c1-b88f-438f-a79f-97cac035a715 --></div><section aria-labelledby="basis-for-recommendation-562" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-562">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 562694a6-b671-4a7d-b2e5-8c6f484f1d76 --><!-- begin field 042115fa-8df9-463b-ba91-923a68a37ca4 --><p>This information is based on the manufacturers' Summary of Product Characteristics for Clenil Modulite [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019a</a>], Flixotide Evohaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>], Asmanex Twisthaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017c</a>], and Pulmicort Turbohaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017b</a>].</p><!-- end field 042115fa-8df9-463b-ba91-923a68a37ca4 --><!-- end item 562694a6-b671-4a7d-b2e5-8c6f484f1d76 --></div></section></section><section aria-labelledby="pregnancy-breastfeeding" class="ChapterBody-module--wrapper--2HCfk "><h3 id="pregnancy-breastfeeding">Can I prescribe inhaled corticosteroids to a woman who is pregnant or breastfeeding?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 54502fea-e80b-4390-a370-378bb3681bdc --><!-- begin field eebfdf42-e713-41e1-9594-b8adb5844bf2 --><ul><li><strong>Pregnancy</strong><ul><li>Inhaled corticosteroids can be used as normal at any stage in pregnancy.</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Inhaled corticosteroids can be used by women who are breastfeeding.</li></ul></li></ul><!-- end field eebfdf42-e713-41e1-9594-b8adb5844bf2 --><!-- end item 54502fea-e80b-4390-a370-378bb3681bdc --></div><section aria-labelledby="basis-for-recommendation-ea4" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ea4">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ea478f76-ab96-4833-bda4-c9f395a278d5 --><!-- begin field 909e9ca2-1f41-4723-866d-48ef0915566b --><h5>Pregnancy</h5><ul><li>These recommendations are based on the <em>British National Formulary</em> (BNF) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>], the UK Teratology Information Service (UKTIS) document <em>Inhaled corticosteroids in pregnancy</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2016</a>], and the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma</em>.<ul><li>No significant association has been demonstrated between major congenital malformations or adverse perinatal outcome and exposure to inhaled corticosteroids [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>].</li></ul></li></ul><h5>Breastfeeding</h5><ul><li>These recommendations are based on the BNF [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>] and the Drugs and Lactation Database (LactMed).<ul><li>The amounts of inhaled corticosteroids absorbed into the maternal bloodstream and excreted into breastmilk are probably too small to affect a breastfed infant [<a class="bibliography-reference internal-reference" href="../../references/index.html">LactMed, 2020</a>].</li></ul></li></ul><!-- end field 909e9ca2-1f41-4723-866d-48ef0915566b --><!-- end item ea478f76-ab96-4833-bda4-c9f395a278d5 --></div></section></section><section aria-labelledby="adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="adverse-effects">What are the adverse effects of inhaled corticosteroids?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 798ea96b-e363-4fce-9925-35eeb1f462c7 --><!-- begin field 321f0fa3-0a11-4cbe-aab7-0db9d0ec1282 --><ul><li><strong>Local adverse effects </strong>of inhaled corticosteroids include:<ul><li>Oral candidiasis, altered taste, dysphonia, hoarseness. </li><li>Paradoxical bronchospasm — uncommon. It is characterized by an immediate increase in wheezing after dosing. </li><li>Rash — if the inhaled corticosteroid is administered through a face mask or nebulizer a steroid rash (reddening and atrophy) may develop on the nose and around the mouth. </li></ul></li><li><strong>Systemic adverse effects</strong> — these occur rarely and are much less likely to occur than with oral corticosteroids and are associated with high doses and prolonged use. <ul><li><strong>Systemic adverse effects include:</strong><ul><li>Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/management/corticosteroids/index.html#adrenal-insufficiency">Adrenal insufficiency</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/index.html">Corticosteroids - oral</a>.</li><li>Behavioural changes, sleep disorders, depression, aggression (predominantly in children). </li><li>Cataracts, glaucoma, central serous chorioretinopathy.</li><li>Bruising. </li><li>Increased susceptibility to infection — for example, upper respiratory tract infections, and pneumonia in people with chronic obstructive pulmonary disorder (COPD).</li><li>Reduced bone mineral density. </li></ul></li><li>In children systemic adverse effects may be associated with doses of over 800 micrograms of beclometasone diproprionate equivalent or more per day (medium doses and above) and include: <br><ul><li>Adrenal suppression — this has been reported very rarely in children taking long-term inhaled corticosteroids and can occur even at standard doses.</li><li>Growth retardation — monitor the height of children receiving prolonged treatment with inhaled corticosteroids annually. </li></ul></li><li>For more information on the systemic adverse effects of corticosteroids, see the section on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/management/corticosteroids/index.html#adverse-effects">Adverse effects</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/index.html">Corticosteroids - oral</a>.</li></ul></li></ul><!-- end field 321f0fa3-0a11-4cbe-aab7-0db9d0ec1282 --><!-- end item 798ea96b-e363-4fce-9925-35eeb1f462c7 --></div><section aria-labelledby="basis-for-recommendation-e74" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-e74">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e7441cb8-7a9a-4415-8922-4c7a319b297e --><!-- begin field 8822da5f-4b08-46ec-b7e2-d1ad265c59c8 --><p>This information is based on the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>], the <em>British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>], the Global Initiative for Asthma (GINA) <em>Global strategy for asthma management and prevention</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA, 2020</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update<em> Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2017</a>], and the manufacturers' Summary of Product Characteristics for Clenil Modulite [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019a</a>], Flixotide Evohaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>], Asmanex Twisthaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017c</a>], and Pulmicort Turbohaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017b</a>].</p><p><strong style="font-family: -apple-system, BlinkMacSystemFont, 'segoe ui', Roboto, Oxygen, Ubuntu, Cantarell, 'open sans', 'helvetica neue', sans-serif;">Systemic adverse effects</strong></p><ul><li><p>Systemic adverse effects of corticosteroids are caused by swallowing some of the dose after deposition on the oropharynx (as well as from systemic absorption from the lungs). Fluticasone, mometasone, and ciclesonide are poorly absorbed from the gastrointestinal tract and undergo almost complete pre-systemic metabolism and so are less likely to cause systematic adverse effects [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ritter, 2020</a>].</p></li></ul><p><strong>Risk of infections</strong></p><ul><li>A systematic review and meta-analysis of 17 randomized controlled trials (n = 15,336) that assessed the association between use of inhaled corticosteroids (ICS) and the risk of upper respiratory tract infection (URTI) found that ICS use in people with asthma increases the risk of URTI [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yang, 2019</a>]. </li><li>A Cochrane systematic review of 43 studies (n = 31,397) that assessed the risk of pneumonia associated with fluticasone and budesonide for chronic obstructive pulmonary disease (COPD) found that, either given alone, or in combination with a long-acting beta-2 agonist, they were associated with an increased risk of serious adverse pneumonia events, but neither significantly affected mortality compared with controls [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kew, 2014</a>].</li><li>In COPD, high-dose ICS should not be used because of the risk of pneumonia [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA, 2020</a>].</li></ul><p><strong>Bone mineral density and fracture risk</strong></p><ul><li>Long-term use of ICS may reduce bone mineral density increasing the risk of fractures. However, the evidence is inconsistent, and the SIGN guideline <em><span property="dc:title">Osteoporosis and the prevention of fragility fractures </span></em>did not form a recommendation on fracture risk in people taking ICS [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2015</a>].<br><ul><li>A systematic review and meta-analysis of seven randomized controlled trials and 11 observational studies that looked at the association of long-term ICS and bone adverse effects in adults and children with asthma found no consistent evidence of serious skeletal harm from use of ICS [<a class="bibliography-reference internal-reference" href="../../references/index.html">Loke, 2015a</a>]. </li><li>A systematic review meta-analysis of 16 randomized controlled trials (RCTs) and seven observational studies in people with COPD found a small, but statistically significant dose-related increase in risk of fracture associated with long-term use of ICS [<a class="bibliography-reference internal-reference" href="../../references/index.html">Loke, 2011</a>]. </li><li>A systematic review and meta-analysis of 13 studies and four RCTs did not show any association between use of ICS and increased risk of any fracture or hip fracture, although a slight increase in risk was noted among users of high-dose ICS [<a class="bibliography-reference internal-reference" href="../../references/index.html">Etminan, 2008</a>].</li></ul></li></ul><p><strong>Adrenal suppression</strong></p><ul><li>Clinical adrenal insufficiency has been identified in a small number of children who have become acutely unwell at the time of intercurrent illness. Most of these children had been treated with high doses of ICS. The dose or duration of ICS treatment required to place a child at risk of clinical adrenal insufficiency is unknown, but is likely to occur at 800 micrograms beclometasone dipropionate equivalent per day or more [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>].</li><li>However, there is evidence that adrenal suppression may also occur in some children at lower doses [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kapadia, 2016</a>].<ul><li>Concomitant nasal corticosteroid use, low body mass index, and cumulative dose of ICS are contributing factors to the development of adrenal suppression.</li></ul></li></ul><p><strong>Growth retardation</strong></p><ul><li>Although the effects of ICS on growth velocity are seen in pre-pubertal children in the first 1–2 years of treatment, this is not progressive or cumulative [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA, 2020</a>] — a systematic review and meta-analysis that examined the impact of ICS on growth in children found a difference of only 0.7% in adult height in ICS users compared with non-ICS users [<a class="bibliography-reference internal-reference" href="../../references/index.html">Loke, 2015b</a>].</li><li>A Cochrane systematic review of 25 trials (n = 8471) that assessed the impact of ICS on the linear growth of children with persistent asthma found that regular use of ICS at low or medium daily doses was associated with a mean reduction of 0.48 cm/year in linear growth velocity and 0.61 cm change from baseline in height during a 1-year treatment period in children with moderate persistent asthma. Other findings included [<a class="bibliography-reference internal-reference" href="../../references/index.html">Zhang, 2014</a>]: <ul><li>The effect size was associated more strongly with the ICS molecule than with the device or dose (in the low to medium range) — both beclometasone and budesonide produced a greater reduction in mean linear growth velocity (0.91 cm/year and 0.59 cm/year, respectively) compared with ciclesonide (0.08 cm/year), flunisolide (0.22 cm/year), fluticasone (0.39 cm/year), and mometasone (0.47 cm/year). </li><li>ICS-induced growth suppression was maximal during the first year of therapy and less pronounced in subsequent years.</li></ul></li><li>A Cochrane systematic review that assessed whether increasing the dose of ICS was associated with linear growth, weight gain, and skeletal maturation in children with asthma, and compared studies reporting linear growth over 12 months that used beclomethasone, budesonide, ciclesonide, fluticasone, or mometasone as monotherapy or as combination therapy with a long-acting beta-2 agonist at low (50 to 100 micrograms) versus low to medium (200 micrograms) doses of hydrofluoroalkane (HFA)-beclomethasone equivalent over 12–52 weeks, found that in four trials reporting the main outcomes [<a class="bibliography-reference internal-reference" href="../../references/index.html">Pruteanu, 2014</a>]:<ul><li>There was a small but statistically significant group difference in growth velocity in the higher dose group — 5.74 cm/year, compared with 5.94 cm/year in lower dose ICS.</li><li>The choice of ICS molecule (mometasone, ciclesonide, or fluticasone) did not affect the level of growth velocity response.</li></ul></li><li>Poorly controlled asthma itself adversely affects growth and final adult height [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA, 2020</a>]. </li><li>The minor growth risks associated with ICS use are outweighed by the respiratory benefits [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kapadia, 2016</a>]. </li></ul><!-- end field 8822da5f-4b08-46ec-b7e2-d1ad265c59c8 --><!-- end item e7441cb8-7a9a-4415-8922-4c7a319b297e --></div></section></section><section aria-labelledby="minimizing-adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="minimizing-adverse-effects">How do I minimize the risks of adverse effects in people using inhaled corticosteroids?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3bf0cc65-659d-4904-b1b0-e01bdd0aa9ae --><!-- begin field df78c24a-6bb9-4d04-a932-ee8aad7f58de --><ul><li><strong>To minimize the adverse effects of inhaled corticosteroids:</strong><ul><li>Ensure that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of symptoms is achieved. If adequate control of symptoms is not achieved, consider using add-on treatments rather than increasing the dose of inhaled corticosteroid. For more information see the CKS topic on <a class="topic-reference external-reference" href="../../../asthma/index.html">Asthma</a>. </li><li>Avoid a rapid reduction in corticosteroid dose after prolonged use to reduce the risk of adrenal insufficiency — in adults who are stable on a high dose, consider halving the dose every 3 months.</li><li>Prescribe a large-volume spacer with a pressurized metered-dose inhaler (pMDI) for all children aged under 5 years and in all other people taking high doses of inhaled corticosteroids.</li></ul></li><li><strong>Oral candidiasis</strong> — advise the person to use a spacer and rinse their mouth with water after using an inhaler, this will also help to reduce systemic absorption of corticosteroid as a result of ingestion.<ul><li>An antifungal oral suspension or oral gel can be used to treat oral candidiasis without discontinuing corticosteroid therapy.</li></ul></li><li><strong>Paradoxical bronchospasm</strong> — advise people with mild bronchospasm to use a short-acting beta-2 agonist before the inhaled corticosteroid, or switch from a pMDI to a dry powder inhaler (DPI). If it is severe, discontinue the inhaled corticosteroid and seek specialist advice.</li><li><strong>Facial rash</strong> — advise that the skin and the mouth should be cleaned shortly after inhalation. </li><li><strong>In children receiving prolonged treatment with a high-dose inhaled corticosteroid:</strong><ul><li>Be alert to the symptoms of adrenal suppression, such as fatigue, weight loss, abdominal pain, headache, nausea, and vomiting, especially during times of illness. For more information, see the section on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/management/corticosteroids/index.html#adrenal-insufficiency">Adrenal insufficiency</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/index.html">Corticosteroids - oral</a>.</li><li>Monitor height regularly and accurately using a growth chart — growth velocity may be lower in the first 1–2 years of treatment. If there is a reduction of growth rate reduce the dose if possible, and/or refer to a paediatrician if required. </li></ul></li></ul><!-- end field df78c24a-6bb9-4d04-a932-ee8aad7f58de --><!-- end item 3bf0cc65-659d-4904-b1b0-e01bdd0aa9ae --></div><section aria-labelledby="basis-for-recommendation-dcc" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-dcc">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item dcc077fa-d86e-4588-8847-d65fdcfdd635 --><!-- begin field a8a1cb71-2918-4bb4-a69f-8876c6e263a2 --><p>This information is based on the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>], the Global Initiative for Asthma (GINA) <em>Global strategy for asthma management and prevention</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA, 2020</a>], and the manufacturers' Summary of Product Characteristics for Clenil Modulite [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019a</a>] and Flixotide Evohaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2020</a>].</p><!-- end field a8a1cb71-2918-4bb4-a69f-8876c6e263a2 --><!-- end item dcc077fa-d86e-4588-8847-d65fdcfdd635 --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">What are the key drug interactions with inhaled corticosteroids and how should I manage them?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 42ebd053-94e0-4a7d-af0f-8568d8a30d65 --><!-- begin field 6313a0aa-eb4e-4486-8bd2-a031d7eb1b43 --><ul><li><strong>Drug interactions are rare in people taking inhaled corticosteroids,</strong> as systemic corticosteroid concentrations are usually low. However, in people taking high doses of inhaled corticosteroids for prolonged periods, systemic corticosteroid concentrations may be sufficiently high for interactions to become significant.</li><li><strong>Antidiabetics</strong> (alogliptin, canagliflozin, glibenclamide, liraglutide, metformin) — the blood-glucose-lowering effects of antidiabetics are opposed by oral corticosteroids and high-dose corticosteroids may have a similar effect. Increase monitoring of diabetic control in people requiring high-dose inhaled corticosteroids and consider reducing the dose of the inhaled corticosteroids or adjusting the dose of antidiabetic medicine if necessary. </li><li>If the person is taking a drug known to inhibit cytochrome P450, be aware that the metabolism of the inhaled corticosteroid may be inhibited, leading to an increased risk of adverse effects — beclometasone is less dependent on P450 (CYP3A) and may be a suitable alternative.  <ul><li><strong>Antiretrovirals</strong> (ritonavir, saquinavir) — concurrent treatment is not recommended as there is potential for an interaction even with inhaled corticosteroids. If concurrent treatment is necessary, monitor for corticosteroid adverse effects (such as moon face, weight gain, hyperglycaemia).<ul><li>Beclometasone can cause hypokalaemia that might be additive with the effects of saquinavir. Monitor potassium levels closely. </li></ul></li><li><strong>Cobicistat</strong> — concurrent treatment is not recommended as there is potential for an interaction even with inhaled corticosteroids. If concurrent treatment is necessary, monitor for corticosteroid adverse effects. </li><li><strong>Azole antifungals</strong> (itraconazole, ketoconazole) — be alert for any unexpected increase in corticosteroid adverse effects.</li></ul></li></ul><!-- end field 6313a0aa-eb4e-4486-8bd2-a031d7eb1b43 --><!-- end item 42ebd053-94e0-4a7d-af0f-8568d8a30d65 --></div><section aria-labelledby="basis-for-recommendation-e31" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-e31">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e310beee-6748-40ea-91a8-05e34ea62f9d --><!-- begin field 6c99507c-9932-48cf-9c6e-55022f582cb1 --><p>These recommendations are based on the textbook <em>Stockley's Drug Interactions</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Preston, 2020</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2016</a>], and the manufacturer's Summary of Product Characteristics for Clenil Modulite [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019a</a>], Alvesco Inhaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017a</a>], and Symbicort Turbohaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019b</a>].</p><h5>Antiretrovirals and inhaled corticosteroids</h5><ul><li>Coadministration of a HIV treatment boosting agent with a CYP3A-metabolized corticosteroid is not recommended unless the potential benefit to the patient outweighs the risk, in which case patients should be monitored for systemic corticosteroid-related reactions [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2016</a>].<ul><li>If coadministration is necessary, use of beclomethasone should be considered where possible — particularly for long-term use. Beclomethasone is less dependent on CYP3A metabolism, and, although the risk of an interaction leading to adverse corticosteroid effects may not be completely removed, it may be lower.</li></ul></li><li>Beclometasone is less dependent on CYP3A metabolism than some other corticosteroids, and, in general, interactions are unlikely, however, the possibility of systemic effects with concomitant use of strong CYP3A inhibitors cannot be excluded [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019a</a>].</li></ul><h5>Azole antifungals and inhaled corticosteroids</h5><ul><li>The manufacturers of Alvesco Inhaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017a</a>] and Symbicort Turbohaler [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019b</a>] recommend that concurrent use with potent cytochrome P450 inhibitors (CYP450), such as azole antifungals, should be avoided, unless the benefits outweigh the risk of systemic adverse effects. <ul><li>If short–term treatment with a CYP450 inhibitor is necessary, the time interval between administration of the inhibitor and Symbicort Turbohaler should be as long as possible [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019b</a>].</li></ul></li></ul><!-- end field 6c99507c-9932-48cf-9c6e-55022f582cb1 --><!-- end item e310beee-6748-40ea-91a8-05e34ea62f9d --></div></section></section><section aria-labelledby="information-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="information-advice">What information and advice should I give to a person receiving inhaled corticosteroids?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 97beee3a-30a1-419c-afa9-a74b90e0453b --><!-- begin field 0391168a-9c7d-4f24-b87f-f43a7aaddf30 --><ul><li><strong>Advise the person taking inhaled corticosteroids (ICS):</strong><ul><li>On the importance of using the correct inhaler technique, and how to take care of the device.<ul><li>To check and remove the mouthpiece cover properly before inhaling a dose and to shake the inhaler to remove loose objects that may have become trapped during storage. </li><li>To replace the inhaler cover immediately after use and to ensure it clicks into place. </li><li>To clean the device according to the manufacturer's instructions. </li></ul></li><li>On the importance of attending for regular review, including monitoring of growth in children.</li><li>That their treatment needs to be taken regularly (usually twice daily), long term, and that there will be no immediate noticeable effect on their symptoms.</li><li>That adherence to the treatment will lead to better control of the condition and decrease the risk of complications.</li><li>That if they are using a spacer device, they should always use the same type and not switch between spacers as they are not inter-compatible.<ul><li>The spacer device should be cleaned regularly in warm water that can contain a mild detergent, or a sterilising solution used to clean babies' bottles. It should then be allowed to air dry. </li><li>Spacer devices should be replaced after 12 months. </li><li>Not to share inhaler devices or spacers with family members. </li></ul></li><li>That smoking can reduce the effectiveness of ICS. </li><li>To rinse their mouth with water after inhaling each dose to reduce the risk of oral candidiasis and systemic absorption. </li><li>If the person has never had chickenpox and is taking high-dose ICS, to avoid people with chickenpox or shingles, and to seek medical advice if they come into contact with an affected person. </li><li>To be aware of the symptoms of adrenal insufficiency and seek immediate medical attention if they experience them. For more information, see the section on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/management/corticosteroids/index.html#adrenal-insufficiency">Adrenal insufficiency</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../corticosteroids-oral/index.html">Corticosteroids - oral</a>. </li><li>To carry a steroid treatment card if they are receiving long-term treatment with high doses. <ul><li>This provides clear guidance on the precautions to minimize the risks of adverse effects, and provides details of the prescriber, drug, dosage, and the duration of treatment.</li></ul></li><li>GP practices can obtain supplies through their Primary Care Support England.</li><li>Advise people taking ICS of the possible adverse effects and ways to minimize them.</li></ul></li><li><strong>COVID-19</strong><ul><li>The advice for people using inhaled steroids for any indication is to continue at the prescribed dose in order to optimise the control of their condition.</li><li>Explain to people that there is no evidence that treatment with ICS increases the risk associated with COVID‑19.</li><li>Advise those people who are using ICS regularly to continue to use them and delay any planned trials of withdrawal of ICS.</li></ul></li></ul><!-- end field 0391168a-9c7d-4f24-b87f-f43a7aaddf30 --><!-- end item 97beee3a-30a1-419c-afa9-a74b90e0453b --></div><section aria-labelledby="basis-for-recommendation-e32" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-e32">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e3269db6-0c6a-42ef-a338-15a2906ba1e5 --><!-- begin field 27a2d6f7-f3db-406c-9ebe-34347ab71679 --><p>These recommendations are based on the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) <em>British guideline on the management of asthma</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>], the Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention [<a class="bibliography-reference internal-reference" href="../../references/index.html">GINA, 2020</a>], the National Institute for Health and Care Excellence (NICE)<em> Chronic obstructive pulmonary disease in over 16s: diagnosis and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>], the <em>British National Formulary </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2018</a>], and the patient information leaflet for Volumatic Adult Spacer [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018</a>].</p><h5>Cleaning spacers</h5><ul><li>The manufacturers of the Volumatic spacer advises people to clean spacers at least twice weekly [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018</a>]. However, NICE advises that cleaning should be carried out no more than once monthly as more frequent cleaning affects their performance because of build up of static [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019b</a>].  </li></ul><h5>Chickenpox and measles</h5><ul><li>People taking high-dose inhaled corticosteroids (ICS) should be issued with a steroid treatment card [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2020</a>]. <ul><li>The steroid treatment card advises people that have never had chickenpox to avoid people with chickenpox or shingles, and to seek medical advice if they come into contact with an infected person. The <em>BNF</em> states that this advice should also apply to measles. </li><li>The steroid treatment card does not make a distinction between oral corticosteroids and ICS, and while the <em>BNF</em> advises that this advice applies to people receiving oral or parenteral corticosteroids, it does not extend this advice to people taking ICS. </li><li>CKS could find no evidence that people taking high-dose ICS are at increased risk from chickenpox, so the recommendation to provide advice to avoid people with chickenpox or shingles if they are taking high-dose ICS is pragmatic as high-dose ICS may cause immunosuppression [<a class="bibliography-reference internal-reference" href="../../references/index.html">BTS/SIGN, 2019</a>].</li></ul></li></ul><h5>COVID-19</h5><ul><li>The recommendation to continue using ICS during the COVID-19 pandemic is based on the National Institute for Health and Care Excellence (NICE) <em>COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020a</a>] and <em>COVID-19 rapid guideline: severe asthma NICE guideline</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020b</a>]. <ul><li>The recommendation to continue using ICS in COPD is based on NICE guidelines that advise that ‘there is some evidence that use of ICS in COPD may increase the overall risk of pneumonia this risk alone should not be used as a reason to change treatment in those established on ICS’ as this may cause a resultant risk and destabilisation of COPD management.</li></ul></li></ul><!-- end field 27a2d6f7-f3db-406c-9ebe-34347ab71679 --><!-- end item e3269db6-0c6a-42ef-a338-15a2906ba1e5 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/corticosteroids-inhaled/management/corticosteroids-inhaled/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>